The prognosis and treatment outcomes of patients with recurrent hepatocellular carcinoma after liver transplantation

Clinical Transplantation

Volumn 28, Issue 1, 2014, Pages 141-147

  Roh, Young Nam ^a   David Kwon, Choon Hyuck ^b   Song, Sanghyun ^b   Shin, Milljae ^b   Man Kim, Jong ^b   Kim, Sungjoo ^b   Joh, Jae Won ^b   Lee, Suk Koo ^b  

^a Inje University College of Medicine   (South Korea)

^b Sungkyunkwan University School of Medicine   (South Korea)

Author keywords

Locoregional treatment; Metastasis; MTOR inhibitor; Rapamycin; Sorafenib

Indexed keywords

ALPHA FETOPROTEIN; CYCLOSPORIN; TACROLIMUS;

ADULT; AGED; ALCOHOL LIVER DISEASE; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; AUTOIMMUNE HEPATITIS; BONE METASTASIS; BONE SCINTISCANNING; BUDD CHIARI SYNDROME; CANCER COMBINATION CHEMOTHERAPY; CANCER GRADING; CANCER GROWTH; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHILD PUGH SCORE; COMPUTER ASSISTED TOMOGRAPHY; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS C; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LIVER CELL CARCINOMA; LIVER HISTOLOGY; LIVER TRANSPLANTATION; LOCAL THERAPY; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MIDDLE AGED; PORTAL VEIN; POSITRON EMISSION TOMOGRAPHY; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; RETROSPECTIVE STUDY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMIC THERAPY; THORAX RADIOGRAPHY; TREATMENT OUTCOME; TUMOR DIFFERENTIATION;

LOCOREGIONAL TREATMENT; METASTASIS; MTOR INHIBITOR; RAPAMYCIN; SORAFENIB;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FEMALE; FOLLOW-UP STUDIES; HUMANS; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 84892380014     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/ctr.12286     Document Type: Article

References (18)

1. Mazzaferro V, Llovet JM, Miceli R et al. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol 2009: 10: 35.
2. Yao FY, Ferrell L, Bass NM et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 2001: 33: 1394.
3. Cescon M, Ravaioli M, Grazi GL et al. Prognostic factors for tumor recurrence after a 12-year, single-center experience of liver transplantations in patients with hepatocellular carcinoma. J Transplant 2010: 2010.
4. Chinnakotla S, Davis GL, Vasani S et al. Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantation. Liver Transpl 2009: 15: 1834.
5. Escartin A, Sapisochin G, Bilbao I et al. Recurrence of hepatocellular carcinoma after liver transplantation. Transplant Proc 2007: 39: 2308.
6. Hollebecque A, Decaens T, Boleslawski E et al. Natural history and therapeutic management of recurrent hepatocellular carcinoma after liver transplantation. Gastroenterol Clin Biol 2009: 33: 361.
7. Regalia E, Fassati LR, Valente U et al. Pattern and management of recurrent hepatocellular carcinoma after liver transplantation. J Hepatobiliary Pancreat Surg 1998: 5: 29.
8. Roayaie S, Schwartz JD, Sung MW et al. Recurrence of hepatocellular carcinoma after liver transplant: patterns and prognosis. Liver Transpl 2004: 10: 534.
9. Schwartz M, Roayaie S, Llovet J. How should patients with hepatocellular carcinoma recurrence after liver transplantation be treated? J Hepatol 2005: 43: 584.
10. Shin WY, Suh KS, Lee HW et al. Prognostic factors affecting survival after recurrence in adult living donor liver transplantation for hepatocellular carcinoma. Liver Transpl 2010: 16: 678.
11. Vivarelli M, Dazzi A, Zanello M et al. Effect of different immunosuppressive schedules on recurrence-free survival after liver transplantation for hepatocellular carcinoma. Transplantation 2010: 89: 227.
12. Kwon CH, Kim DJ, Han YS et al. HCC in living donor liver transplantation: can we expand the Milan criteria? Dig Dis 2007: 25: 313.
13. Jonas S, Bechstein WO, Steinmuller T et al. Vascular invasion and histopathologic grading determine outcome after liver transplantation for hepatocellular carcinoma in cirrhosis. Hepatology 2001: 33: 1080.
14. Tamura S, Kato T, Berho M et al. Impact of histological grade of hepatocellular carcinoma on the outcome of liver transplantation. Arch Surg 2001: 136: 25.
15. Toso C, Merani S, Bigam DL, Shapiro AM, Kneteman NM. Sirolimus-based immunosuppression is associated with increased survival after liver transplantation for hepatocellular carcinoma. Hepatology 2010: 51: 1237.
16. Kim R, El-Gazzaz G, Tan A et al. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation. Oncology 2010: 79: 62.
17. Llovet JM, Ricci S, Mazzaferro V et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 2008: 359: 378.
18. Yeo W, Mok TS, Zee B et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005: 97: 1532.